In June, the European Pharmacopoeia Commission adopted a groundbreaking cannabis flower monograph, marking a significant milestone for the cannabis industry. This official document provides essential guidelines for herbal drug specifications, representing the first modern cannabis monograph in a widely accepted pharmacopeia. The German progress on their legislation will likely have an enormous impact on the Canadian cannabis export business framework.
Key Points:
- Historical Development: The European Pharmacopoeia Commission recently approved a comprehensive cannabis flower monograph, a pivotal event in the cannabis industry. This monograph offers crucial guidelines for herbal drug specifications.
- Purpose of the Monograph: The cannabis flower monograph outlines fundamental details such as the proper collection and processing of dried cannabis samples. It complements the general monograph on Herbal drugs, incorporating pertinent requirements.
- Availability and Publication: The monograph is accessible online and is slated for publication in the European Pharmacopoeia (Ph. Eur.) Supplement 11.5 in January 2024. It will serve as a vital resource for companies exporting cannabis to Europe.
- Implementation Timeline: The European Directorate for the Quality of Medicines & HealthCare (EDQM) plans to host a webinar on December 14, 2023, introducing the new monograph to its members. The official implementation is anticipated by July 1, 2024.
- Stringent Regulations: The monograph incorporates insights from various national authorities regarding cannabis usage, including specific limits for arsenic, cadmium, and lead, especially in cases where the herbal drug is prescribed to patients. These regulations ensure the safety and quality of cannabis products.
- International Impact: The monograph’s influence extends beyond Europe. Canadian cannabis companies exporting to Europe will be significantly affected, as the monograph sets the standard for acceptable variations in cannabis products, distinguishing between medical and non-medical purposes.
- Industry Responses: Industry experts and associations acknowledge the monograph’s importance. It clarifies cannabis chemotype classification, establishing precise tests for identification, foreign matter content, loss on drying, heavy metals, and cannabinoid content. Analytical testing labs are gearing up to adapt to these changes, recognizing the monograph’s global significance.
- Global Influence: The European Pharmacopoeia’s influence in Canadian and international cannabis markets is substantial. Including a dedicated cannabis monograph underscores the plant’s increasing acceptance and offers essential guidelines for producers worldwide.
- Broader Implications: The impact of this monograph extends far beyond Europe and Canada. It is poised to shape the trajectory of the US Pharmacopeia, which is also in the process of developing its cannabis-specific monograph, reinforcing the importance of standardized regulations in the global cannabis industry.
This monumental development heralds a new era for cannabis regulation, emphasizing international collaboration and standardized guidelines to ensure the quality and safety of cannabis products worldwide.
How can we help?
At Cannabis License Experts, we provide you with the guidance to plan your cannabis business, acquire funding, navigate the legal requirements, and acquire the appropriate cannabis license for your operations.
Cannabis License Experts offers support from day one of starting your cannabis business, including strategic planning, floor plan preparation, site audits, SOPs, Preventive Control Plans (PCPs), and more.
Our Edibles Compliance division can provide you with a solid plan for your edibles business to help get your products on store shelves.
Contact us today to discover how we can license and legalize your cannabis business to meet federal or provincial regulations.
